AXL and neoplasm: Finally, due to the design control inherent to in vitro experiments, we were able to consider tumor cell state, i.e., untreated vs. injured through treatment with targeted therapeutics, as a variable necessary to gain a mechanistic understanding of Axl inhibition in the distinct contexts of a treatment-naïve tumor microenvironment versus a tumor microenvironment defined by prior standard-of-care treatment (Figure 7) – a comparison which, to the best of our knowledge, has not been reported on previously.